Levetiracetam Tablet, Film Coated
Product Images NDC 48433-052

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 48433-052). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Safecor Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Responder Rate (≥ 50% Reduction From Baseline) In Study 1 (Image 01)

This text provides information about the percentage change observed in a study comparing an unknown treatment (referred to as "Loveiraceam") to a placebo. It mentions a statistically significant difference in the results compared to the placebo group. The specifics of the study or the treatments are not fully clear from the text.*

FDA Label Image

Levetiracetam 500 mg Tablets, Usp Unit Carton Label (Image 02)

This is information about Levetiracetam tablets with the NDC code 48433-052-20. It includes details about the dosage, storage instructions, and the manufacturer, Mylan Pharmaceuticals Inc. It is important to follow the prescribing information provided and store the tablets at a controlled room temperature.*

FDA Label Image

Unit Carton (Image 03)

This text provides information about a glucose package that is not heat resistant. It is intended for institutional use. The package contains alcohol swabs for cleaning the skin before a medical procedure, and the container provides light resistance. The distributor is Safecor Health LLC located in Rockford, USA. For more information, you can contact them at 1-800-447-1006 or visit SafecorHealth.com.*

FDA Label Image

Levetiracetam Structural Formula (Image 05)

FDA Label Image

Pedatric Patient Dose Calculation (Image 06)

Calculate the total daily dose in milliliters by multiplying the daily dose in milligrams per kilogram per day by the patient's weight in kilograms, then divide by 100 mg/mL. This calculation helps determine the required amount of medication a patient needs each day.*

FDA Label Image

Creatinine Clearance Calculation (Image 07)

This is a formula for calculating the creatinine clearance rate for patients. It involves the patient's age, weight, gender (for female patients), and serum creatinine level. The formula considers the age and weight of the patient, with adjustments for gender in the case of female patients. The calculation is an important aspect of determining kidney function in medical assessments.*

FDA Label Image

Creatinine Clearance Bsa Calculation (Image 08)

FDA Label Image

Figure 2: Responder Rate (≥ 50% Reduction From Baseline) In Study 2: Period A (Image 09)

FDA Label Image

Figure 3: Responder Rate (≥ 50% Reduction From Baseline) In Study 3 (Image 10)

This is a report showing a statistical significance of 39.4% versus placebo in a study involving 144 participants.*

FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Image 11)

This text appears to be a pharmaceutical study result showing the percentage change in outcome with a particular treatment compared to a placebo. The results highlight a statistically significant improvement compared to the placebo group.*

FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Image 12)

This text shows a comparison between a placebo group with 51 participants and a drug called Levtraceam Tabies. The results indicate that Levtraceam Tabies had a statistically significant effect compared to the placebo.*

FDA Label Image

Figure 6: Responder Rate (≥ 50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Image 13)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.